# How to keep the weight off after a GLP-1 · PepVault guides

Source: https://pepvault.app/guides/keeping-weight-off-after-a-glp-1

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [GLP-1s](https://pepvault.app/guides#glp1)

# How to keep the weight off after a GLP-1: what each trial tested

Reviewed November 2026 12 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

What each trial tested for keeping weight off after a GLP-1: staying on, a lower dose, switching to a pill and exercise, with every result in one by-drug table.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 12
- **Questions:** 7
- **Compounds:** 4

## The short answer

Staying on the drug kept the weight off best. In SURMOUNT-MAINTAIN, people who stayed on their top tirzepatide dose ended 112 weeks 21.9% below their starting weight, those cut to 5 mg 16.6% and those switched to placebo 9.9%. Moving from the shot to the orforglipron pill kept three-quarters of the loss or more. A year of supervised exercise still held a year after it ended.

Every number checked at its primary source · Nov 20, 2026 · [12 sources](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** Randomised, double-blind trials in people (STEP 4, SURMOUNT-4, SURMOUNT-MAINTAIN, ATTAIN-MAINTAIN and the Lundgren exercise trial with its one-year follow-up), the STEP 1 off-treatment extension, and the FDA labels for Wegovy, Zepbound and Foundayo; the four drug-company trials were funded by the drug's maker.

## Which ways of keeping the weight off have trials tested?

Trials have now tested five strategies: stopping (a switch to placebo, a dummy shot or pill with no drug in it), staying on the drug, dropping to a lower dose, switching from the shot to a pill, and exercise. Each trial first let people lose weight, then split them at random into groups and followed them for about a year[1](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-1) [3](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-3) [4](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-4) [5](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-5) [7](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-7).

| Strategy | Trial and drug | Down at the split | What happened over the next year |
| --- | --- | --- | --- |
| Stop everything | STEP 1 extension, semaglutide 2.4 mg, with the diet and activity programme stopped too | 17.3% at week 68 | 11.6 points of the starting weight regained by week 120, about two-thirds of the loss; 5.6% below the start[6](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-6) |
| Stop (switch to placebo) | STEP 4, semaglutide 2.4 mg | 10.6% at week 20 | Up 6.9% from the weight at the switch over 48 weeks[5](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-5) |
| Stop (switch to placebo) | SURMOUNT-4, tirzepatide 10 or 15 mg | 20.9% at week 36 | Up 14.0% from the weight at the switch over 52 weeks; 16.6% kept at least 80% of their loss[4](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-4) |
| Stay on the drug | STEP 4, semaglutide 2.4 mg | 10.6% at week 20 | A further 7.9% lost over 48 weeks[5](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-5) |
| Stay on the drug | SURMOUNT-4, tirzepatide 10 or 15 mg | 20.9% at week 36 | A further 5.5% lost; 89.5% kept at least 80% of their loss; 25.3% below the start at week 88[4](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-4) |
| Stay on the top dose | SURMOUNT-MAINTAIN, tirzepatide 10 or 15 mg | After 60 weeks on the top dose | All of the loss kept on average in Lilly's on-treatment analysis; 21.9% below the start at week 112 in the paper's main analysis[1](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-1) [2](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-2) |
| Lower dose | SURMOUNT-MAINTAIN, tirzepatide cut to 5 mg | After 60 weeks on the top dose | All but 5.6 kg of the loss kept in Lilly's on-treatment analysis; 16.6% below the start at week 112 in the paper's main analysis, against 9.9% on placebo[1](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-1) [2](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-2) |
| Shot to pill | ATTAIN-MAINTAIN, tirzepatide shot to orforglipron | 21.5% at the switch | 16.8% below the start a year later; 74.7% of the loss kept by those whose weight had levelled off before the switch, against 49.2% on placebo[3](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-3) |
| Shot to pill | ATTAIN-MAINTAIN, semaglutide shot to orforglipron | 16.5% at the switch | 15.1% below the start a year later; 79.3% of the loss kept by those whose weight had levelled off, against 37.6% on placebo[3](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-3) |
| Exercise | Lundgren trial, supervised exercise with or without liraglutide 3.0 mg, after an 8-week diet | 13.1 kg at the split | Exercise plus liraglutide kept off 9.5 kg more than placebo over the year; exercise alone held its weight a year after the programme ended[7](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-7) [8](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-8) |

Each trial counts from its own starting point, so the percentages compare groups inside one trial best, not one trial with another. And from about six months in, SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN offered the drug back to anyone who regained about half of their loss or more, so their placebo groups are not a clean stop[1](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-1) [3](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-3).

<!--promo-->

PepVault's weight log draws a smoothed trend under your weigh-ins, and once you reach your goal it counts the days the trend has held within reach of it: what these trials were measuring. [Track your weight in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-keeping-weight-off-after-a-glp-1-i&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

PepVault's weight log draws a smoothed trend under your weigh-ins, and once you reach your goal it counts the days the trend has held within reach of it: what these trials were measuring.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## Does staying on the drug keep the weight off?

Yes, in every trial that tested it. In STEP 4, people who stayed on semaglutide 2.4 mg kept losing for another 48 weeks while the placebo group regained[5](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-5). In SURMOUNT-4, nine in ten of those who stayed on tirzepatide kept at least 80% of what they had lost, against one in six on placebo[4](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-4). SURMOUNT-MAINTAIN ran the longest, 112 weeks in all, and those who stayed on their top tolerated dose of tirzepatide (the highest they could take comfortably, 10 or 15 mg) ended 21.9% below where they started[1](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-1).

The labels are written for this. Wegovy, Zepbound and the Foundayo pill are each approved to reduce excess body weight and to maintain that reduction long term, and none of the three sets an end date[9](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-9) [10](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-10) [11](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-11). The SURMOUNT-MAINTAIN authors say long-term treatment is often needed to keep the weight off[1](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-1).

## Does a lower maintenance dose keep the weight off?

Mostly, for tirzepatide. SURMOUNT-MAINTAIN is the one published trial that tested a step down: after 60 weeks on 10 or 15 mg, one group was cut to 5 mg for a year. In the paper's main analysis they ended 16.6% below their starting weight, against 21.9% on the top dose and 9.9% on placebo[1](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-1). Lilly's on-treatment analysis has them keeping all but 5.6 kg of their loss[2](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-2). A quarter of the 5 mg group regained more than half of their loss and took rescue tirzepatide, against 8% on the top dose and 67% on placebo[1](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-1). The authors call 5 mg a possible alternative to stopping and add that responses vary from person to person[1](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-1).

The labels allow lower maintenance doses, the steady dose a treatment settles on after the dose climb. Zepbound's lists 5, 10 or 15 mg once weekly for weight reduction and long-term maintenance, chosen by response and tolerability[9](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-9). Wegovy's injection label lists 1.7 mg or 2.4 mg for adults, with 2.4 mg recommended, and allows a step up to 7.2 mg when more loss is needed[10](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-10). We found no published trial of a lower semaglutide maintenance dose after weight loss. A trial comparing a 16-week step-down of semaglutide with an abrupt stop, in people treated for weight regain after weight-loss surgery, is registered by an Egyptian teaching-hospital group; its record still reads not yet recruiting[12](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-12). Which dose fits is the prescriber's decision.

## With this guide

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Mixing charts

- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)
- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)

### Studies

- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)
- [Semaglutide: 11.85% more weight loss than placebo without diabetes](https://pepvault.app/research/semaglutide-tan-2022)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 31 studies](https://pepvault.app/research#semaglutide)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Mazdutide vs Tirzepatide](https://pepvault.app/peptides/compare/mazdutide-vs-tirzepatide)
- [Tirzepatide vs Liraglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-liraglutide)
- [Tirzepatide vs Dulaglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-dulaglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Maintenance dose](https://pepvault.app/glossary/maintenance-dose)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Indication](https://pepvault.app/glossary/indication)

## Can you switch from a GLP-1 shot to a pill and keep the weight off?

ATTAIN-MAINTAIN tested exactly that. It took 376 people who had just finished SURMOUNT-5, a trial of the tirzepatide and semaglutide shots, and moved them straight to daily orforglipron (sold as Foundayo) or to a placebo pill for a year[3](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-3). Those who came from semaglutide held almost everything: 16.5% below their starting weight at the switch, 15.1% a year later. Those who came from tirzepatide gave back about five percentage points: 21.5% at the switch, 16.8% a year later[3](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-3).

The move itself went smoothly. People started on a 12 mg capsule (the trial's capsule, equal to the 9 mg Foundayo tablet), a middle step of the pill's dose climb, instead of the lowest dose, and no one needed a lower dose in the first four weeks[3](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-3). The trial had no group that stayed on the injection, so it cannot say whether the pill holds weight as well as the shot it replaced[3](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-3). Foundayo's label carries the maintenance indication but gives no rule for moving over from an injection[11](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-11).

## Does exercise help keep the weight off after a GLP-1?

It is the one strategy whose effect outlasted the treatment. In the Lundgren trial in Copenhagen, 195 adults first lost 13.1 kg on an 8-week low-calorie diet, then spent a year on supervised exercise, daily liraglutide 3.0 mg (an older, daily GLP-1 shot), both, or neither[7](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-7). Over that year, both together kept off the most, 9.5 kg more than placebo, with about twice the drop in body-fat percentage of either one alone[7](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-7).

Then the treatment stopped, and the researchers weighed people again a year later. The exercise group had kept its weight and body composition. The liraglutide-only group regained 6.0 kg more than the exercise group over that year, and the combination group ended 5.1 kg lighter than the liraglutide-only group, counted from the start of the year of treatment[8](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-8). A year on, the former exercisers still reported a median of 240 minutes a week of moderate to vigorous activity, against 30 minutes for those who had taken liraglutide alone[8](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-8). The trial used liraglutide, not semaglutide or tirzepatide, and we found no published trial that has run the same test with the newer shots.

**Commonly reported:** hunger coming back over a few weeks after the last shot rather than overnight; people settling on a lower dose with their prescriber and holding steady; and others spacing doses further apart, a pattern no trial here has tested.

## What did the people who kept the weight off do in the trials?

What the trials had people do, in order, told as what was studied, not as a plan for anyone:

1. Lost the weight first on the drug's full dose climb: 20 weeks in STEP 4, 36 in SURMOUNT-4 and 60 in SURMOUNT-MAINTAIN[1](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-1) [4](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-4) [5](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-5).
2. Stayed on the drug once the weight had dropped: semaglutide 2.4 mg weekly in STEP 4, tirzepatide 10 or 15 mg weekly in SURMOUNT-4, or 5 mg weekly in SURMOUNT-MAINTAIN's lower-dose group[1](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-1) [4](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-4) [5](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-5).
3. Or moved from the shot to a daily orforglipron pill, starting at the 12 mg capsule (equal to the 9 mg tablet) and climbing to the top tolerated dose, in ATTAIN-MAINTAIN[3](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-3).
4. Kept lifestyle counselling on healthy eating and physical activity going the whole time, as every group in STEP 4, SURMOUNT-4 and ATTAIN-MAINTAIN did[3](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-3) [4](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-4) [5](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-5).
5. In the exercise trial, built up over six weeks, then were asked to do two supervised group sessions a week of hard indoor cycling and circuit training plus two sessions of moderate to vigorous exercise on their own, for a year[8](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-8).
6. Were weighed through the year, so a regain showed early: the two newest trials offered the drug back to anyone who had regained about half of their loss or more[1](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-1) [3](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-3).

<!--promo-->

If your plan is to stay on a weekly shot, PepVault can remind you around the dose time you set for each compound, so the maintenance dose lands on its day. [Set reminders in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-keeping-weight-off-after-a-glp-1-i&mt=8)

<!--/promo-->

## How many in the placebo groups needed the drug back?

Most of them, in the two newest trials. In ATTAIN-MAINTAIN, only 31.3% of the placebo group that came from tirzepatide, and 18.2% of the group that came from semaglutide, got through the 52 weeks without rescue treatment or another weight medicine[3](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-3). In SURMOUNT-MAINTAIN, two-thirds of the placebo group regained more than half of their loss and took rescue tirzepatide[1](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1#source-1). The regain after a stop, week by week and drug by drug, is in our guide on stopping a GLP-1.

These are trial averages and the labels' doses, not a plan for continuing, lowering, switching or stopping any one person's treatment; that decision is made with the prescriber.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. Horn DB et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2026. [PubMed 42119587](https://pubmed.ncbi.nlm.nih.gov/42119587/)
2. Eli Lilly and Company. Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials. Press release, May 12, 2026. [investor.lilly.com](https://investor.lilly.com/node/54261)
3. Aronne LJ et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026. [PubMed 42120723](https://pubmed.ncbi.nlm.nih.gov/42120723/)
4. Aronne LJ et al.; SURMOUNT-4 Investigators. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024. [PubMed 38078870](https://pubmed.ncbi.nlm.nih.gov/38078870/)
5. Rubino D et al.; STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021. [PubMed 33755728](https://pubmed.ncbi.nlm.nih.gov/33755728/)
6. Wilding JPH et al.; STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022. [PubMed 35441470](https://pubmed.ncbi.nlm.nih.gov/35441470/)
7. Lundgren JR et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021. [PubMed 33951361](https://pubmed.ncbi.nlm.nih.gov/33951361/)
8. Jensen SBK et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClinicalMedicine. 2024. [PubMed 38544798](https://pubmed.ncbi.nlm.nih.gov/38544798/)
9. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information. DailyMed, revised August 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)
10. Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information. DailyMed, revised June 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)
11. Eli Lilly and Company. FOUNDAYO (orforglipron) tablets, prescribing information. DailyMed, August 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62)
12. ClinicalTrials.gov NCT07859176. Tapered versus abrupt discontinuation of semaglutide after treatment of recurrent weight gain or suboptimal response following metabolic and bariatric surgery (sponsor General Committee of Teaching Hospitals and Institutes, Egypt). Not yet recruiting (record last updated October 2026). [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859176)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · GLP-1

Guide · GLP-1

### [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)

People lost 14.9% of body weight on a GLP-1, about 2% on metformin, under 1 kg on berberine. Metformin is not a GLP-1. Weight and HbA1c trials, side by side.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [Tirzepatide Studied range: 2.5–15 mg](https://pepvault.app/peptides/tirzepatide)
- [Semaglutide Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/semaglutide)
- [Orforglipron Studied range: 0.8–17.2 mg](https://pepvault.app/peptides/orforglipron)
- [Liraglutide Studied range: 0.6–3 mg](https://pepvault.app/peptides/liraglutide)

## Related guides

- Guide · GLP-1s

  ### [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)

  What happened to weight when semaglutide and tirzepatide were stopped in STEP 1, STEP 4 and SURMOUNT-4: how much came back, how fast, and what the labels say.

  Read the guide
- Guide · GLP-1s

  ### [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)

  No label converts one GLP-1 to another. What the labels say on each switch, Ozempic to Zepbound, shot to pill, CagriSema, and what the switch trials found.

  Read the guide
- Guide · GLP-1s

  ### [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)

  How much weight lost on a GLP-1 is lean mass: SURMOUNT-1, STEP 1, the apitegromab and bimagrumab add-on trials, and what guidance says on protein and training.

  Read the guide
- Guide · GLP-1s

  ### [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)

  Aleniglipron is Structure Therapeutics' daily GLP-1 pill in testing: its phase 2 numbers, every trial, and what its shot-to-pill SWITCH trial must beat.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Mixing charts

- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)
- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)

### Studies

- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)
- [Semaglutide: 11.85% more weight loss than placebo without diabetes](https://pepvault.app/research/semaglutide-tan-2022)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 31 studies](https://pepvault.app/research#semaglutide)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Mazdutide vs Tirzepatide](https://pepvault.app/peptides/compare/mazdutide-vs-tirzepatide)
- [Tirzepatide vs Liraglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-liraglutide)
- [Tirzepatide vs Dulaglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-dulaglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Maintenance dose](https://pepvault.app/glossary/maintenance-dose)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Indication](https://pepvault.app/glossary/indication)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
